

# **RGL4 Antibody (N-term) Blocking Peptide**

Synthetic peptide Catalog # BP17597a

## **Specification**

### RGL4 Antibody (N-term) Blocking Peptide - Product Information

**Primary Accession** 

**081Z14** 

## RGL4 Antibody (N-term) Blocking Peptide - Additional Information

**Gene ID 266747** 

#### **Other Names**

Ral-GDS-related protein, hRGR, Ral guanine nucleotide dissociation stimulator-like 4, RalGDS-like 4, RGL4, RGR

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### RGL4 Antibody (N-term) Blocking Peptide - Protein Information

Name RGL4

Synonyms RGR

# **Cellular Location**

Cytoplasmic vesicle.

### **RGL4 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

#### • Blocking Peptides

RGL4 Antibody (N-term) Blocking Peptide - Images

### RGL4 Antibody (N-term) Blocking Peptide - Background

Ral GDS (Ral guanine nucleotide dissociation stimulator) is a guanine nucleotide exchange factor (GEF) that activates Ral and is implicated in oncogenic Ras-induced cell transformation. RGL4 (ral





Tel: 858.875.1900 Fax: 858.875.1999

guanine nucleotide dissociation stimulator-like 4), also known as Rgr, is a 473 amino acid protein that localizes to the cytoplasmic vesicle of cells. Belonging to the GEF family of proteins, RGL4 induces phosphorylation of ERKs, p38 and JNK kinases, and it increases the levels of GTP bound forms of Ral and Ras. Ras activation is crucial for the transforming activity of RGL4. Due to its similarity to Ral GDS, RGL4 may be implicated in carcinogenesis.

### **RGL4 Antibody (N-term) Blocking Peptide - References**

Hernandez-Munoz, I., et al. Cancer Res. 63(14):4188-4195(2003)Hernandez-Munoz, I., et al. Oncogene 19(23):2745-2757(2000)Dunham, I., et al. Nature 402(6761):489-495(1999)D'Adamo, D.R., et al. Oncogene 14(11):1295-1305(1997)